VIVXF (Avivagen) Long-Term Debt: $0.83 Mil (As of Jul. 2023)


What is Avivagen Long-Term Debt?

Avivagen VIVXF -99.00% Long-Term Debt is $0.83 Mil as of Jul. 2023.

Avivagen's Long-Term Debt for the quarter that ended in Jul. 2023 was $0.83 Mil.

Avivagen's quarterly Long-Term Debt declined from Jan. 2023 ($4.03 Mil) to Apr. 2023 ($0.99 Mil) and declined from Apr. 2023 ($0.99 Mil) to Jul. 2023 ($0.83 Mil).

Avivagen's annual Long-Term Debt declined from Oct. 2020 ($3.41 Mil) to Oct. 2021 ($1.12 Mil) but then increased from Oct. 2021 ($1.12 Mil) to Oct. 2022 ($3.84 Mil).

Avivagen  (OTCPK:VIVXF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Avivagen Long-Term Debt Related Terms

Avivagen Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Avivagen's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avivagen Long-Term Debt Chart

Avivagen Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.54 2.91 3.41 1.12 3.84

Avivagen Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.88 3.84 4.03 0.99 0.83
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.83 Mil mean?
Avivagen (VIVXF) has a Long-Term Debt of $0.83 Mil as of Jul. 2023.
Is Avivagen's Long-Term Debt too high?
Avivagen's current Long-Term Debt is $0.83 Mil.
How does Avivagen's Long-Term Debt compare to DMKPQ and MJNE?
Avivagen's Long-Term Debt of $0.83 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Avivagen's current Long-Term Debt is $0.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avivagen stock overvalued right now?
Avivagen (VIVXF) has a current Long-Term Debt of $0.83 Mil. The current Long-Term Debt is $0.83 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Avivagen (VIVXF), the current Long-Term Debt is $0.83 Mil as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avivagen Business Description

Address 100 Sussex Drive, Ottawa, ON, CAN, K1A 0R6
Avivagen Inc OxC-beta technology is derived from Avivagen discoveries about Beta-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxCbeta Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. Avivagen's OxC-beta Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters.